

Attorney Docket No.: 5956.200-US

#7A  
PATENT  
LB  
5/8/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: To be assigned

Filed: September 11, 2000

Group Art Unit: To be assigned

Examiner: To be assigned

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 USC 119 of U.S. provisional application no. 60/156,586 filed on September 29, 1999 and Danish application no. PA 1999 01278 filed on September 10, 1999, the contents of which are fully incorporated herein by reference.--

IN THE CLAIMS:

Please cancel claims 30, 31, 38, 40, 43, 48, 49, 53, 55, 62, 74, 75, 78-84, 87-89, 92, 95 and 98 without prejudice or disclaimer.

REMARKS

This preliminary amendment is being submitted simultaneously with the filing of the present application. By this amendment, applicants have canceled claims 30, 31, 38, 40, 43, 48, 49, 53, 55, 62, 74, 75, 78-84, 87-89, 92, 95 and 98. Therefore, claims 1-29, 32-37, 39, 41, 42, 44-47, 50-52, 54, 56-61, 63-73, 76, 77, 85, 86, 90, 91, 93, 94, 96, 97 and 99 are

pending. Since no new matter has been added by this amendment, early examination and favorable consideration of the present application is earnestly solicited.

Respectfully submitted,

Date: September 11, 2000

Carol E. Rozek  
Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

00760 45429360